Answers are grounded in this paper and cite their sources.
Background: Activated immune cells show an enhanced glucose metabolism, suggesting that the inhibition of this pathway selective in immune cells could be a potential approach to combat inflammatory diseases. We studied here whether ADP-dependent glucokinase (ADPGK), a glucose-phosphorylating enzyme predominantly expressed in immune cells, could be a suitable target for the inhibition of macrophage activation. Methods: The regulation and role of ADPGK in human primary macrophages differentiated from blood monocytes was studied using Real-time quantitative PCR (RT-qPCR), gene silencing, whole-cell MALDI-mass spectrometry (MS) imaging as well as immune-based and enzymatic medium analyzes. Results: The expression of ADPGK was induced in response to the activation of toll-like receptors (TLRs). The most robust effect was observed with the TLR4 ligand Lipopolysaccharide (LPS) leading to an approximately 4-fold increase of ADPGK RNA levels. For this induction, the activation of p38 MAPK and IKKε was important. Silencing of ADPGK expression using siRNAs had neither an effect on LPS-induced expression and release of proinflammatory cytokines nor on cellular ATP levels and lactate production. Untargeted metabolic cell profiling by whole-cell MALDI-MS imaging did not reveal any metabolic regulations after ADPGK down-regulation suggesting no specific metabolic pathway involvement. Conclusions: ADPGK neither catalyzes a rate-limiting step of glucose metabolism in LPS-activated macrophages nor is required for the proinflammatory phenotype of these cells in vitro. Our data do not indicate that ADPGK inhibition could be a pharmacological approach to modulate immunometabolism.
No takes yet. Share an insight, caveat, or question.
Geiger et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: